NPI: 1407892243 · NASHVILLE, TN 37228 · Clinical Medical Laboratory · NPI assigned 06/21/2006
Authorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
| Authorized Official | BOWLES, CHARLES (VICE PRESIDENT) |
| Parent Organization | QUEST DIAGNOSTICS INCORPORATED |
| NPI Enumeration Date | 06/21/2006 |
Other providers sharing the same authorized official: BOWLES, CHARLES
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,272 | $275.13 |
| 2019 | 535 | $119.84 |
| 2020 | 2,674 | $1K |
| 2021 | 28,570 | $6K |
| 2022 | 28,225 | $118.09 |
| 2023 | 30,631 | $132.41 |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80061 | Lipid panel | 11,016 | 8,187 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | 8,976 | 6,557 | $1K |
| 80053 | Comprehensive metabolic panel | 16,036 | 12,051 | $956.80 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3,091 | 2,103 | $941.18 |
| 83036 | Hemoglobin; glycosylated (A1C) | 7,236 | 5,452 | $703.41 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12,490 | 9,374 | $573.56 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 904 | 702 | $533.60 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 889 | 666 | $386.91 |
| 82607 | 1,961 | 1,313 | $328.17 | |
| 84153 | 712 | 476 | $201.49 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,751 | 1,341 | $132.83 |
| 82746 | 876 | 556 | $121.74 | |
| 83970 | 942 | 639 | $105.28 | |
| 87088 | 1,404 | 1,075 | $98.29 | |
| 84439 | 1,908 | 1,434 | $82.60 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 556 | 379 | $77.26 |
| 82043 | 2,443 | 1,893 | $64.00 | |
| 85027 | 1,848 | 1,303 | $58.82 | |
| 82728 | 996 | 695 | $58.15 | |
| 82570 | 2,378 | 1,808 | $48.99 | |
| 80074 | 37 | 24 | $44.06 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 295 | 218 | $42.60 |
| 83550 | 999 | 693 | $39.36 | |
| 86038 | 638 | 438 | $38.96 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 945 | 788 | $38.95 |
| 83540 | 1,168 | 785 | $38.75 | |
| 87186 | 792 | 589 | $36.46 | |
| 86803 | 860 | 563 | $35.49 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 451 | 320 | $29.64 |
| 87077 | 771 | 597 | $29.13 | |
| 81001 | 1,255 | 914 | $23.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 306 | 226 | $14.30 |
| 86140 | 664 | 500 | $12.88 | |
| 83735 | 734 | 500 | $12.42 | |
| 87522 | Neg quan hep c or qual rna | 24 | 12 | $10.44 |
| 86592 | 578 | 369 | $10.04 | |
| 85652 | 692 | 529 | $7.92 | |
| 84550 | 587 | 433 | $5.88 | |
| 84436 | 216 | 152 | $3.23 | |
| 86376 | 45 | 27 | $3.20 | |
| 86431 | 243 | 181 | $3.04 | |
| 86039 | 59 | 37 | $2.70 | |
| 84479 | 123 | 85 | $2.21 | |
| 82248 | 75 | 49 | $1.95 | |
| 82550 | 91 | 56 | $0.90 | |
| 84156 | 45 | 38 | $0.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 193 | 129 | $0.00 |
| 82652 | 52 | 42 | $0.00 | |
| 86200 | 15 | 13 | $0.00 | |
| 84100 | 28 | 24 | $0.00 | |
| 85610 | 39 | 18 | $0.00 | |
| 84481 | 178 | 137 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 68 | 62 | $0.00 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 58 | 51 | $0.00 |
| 83880 | 684 | 473 | $0.00 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 199 | 139 | $0.00 |
| 83690 | 13 | 12 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 90 | 73 | $0.00 |
| 87340 | 58 | 46 | $0.00 | |
| 84480 | 25 | 13 | $0.00 | |
| 86704 | 38 | 29 | $0.00 | |
| 87070 | 46 | 38 | $0.00 | |
| 86706 | 17 | 12 | $0.00 |